A |
Both strong evidence for efficacy and substantial clinical benefit support recommendation for use. Should always be offered
|
B |
Moderate evidence for efficacy—or strong evidence for efficacy, but only limited clinical benefit—supports recommendation for use. Should generally be offered.
|
C |
Evidence for efficacy is insufficient to support a recommendation for or against use, or evidence for efficacy might not outweigh adverse consequences, (e.g., drug toxicity, drug interactions), or cost of the chemoprophylaxis or alternative approaches. Optional. |
D |
Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be offered. |
E |
Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered. |